Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Farma ondernemingen’

Abbvie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3

Abbvie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own best-selling blockbuster Humira (adalimumab) at Phase 3 in the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to methotrexate, hitting both its primary and secondary endpoints.

Bron: Pharmafile Meer lezen »

Sobi receives expanded EU approval for Kineret

Joining its current indication as a treatment for rheumatoid arthritis and cryopyrin-associated periodic syndromes, Sobi’s Kineret has been given approval by the European Commission to include an indication for Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease.

Bron: Pharmafile Meer lezen »

Shire dropped oncology unit for $2.4bn, unbalancing Takeda deal

Shire has announced that it has entered a definitive agreement for French drugmaker Servier to take on its oncology business.

Bron: Pharmafile Meer lezen »

Keytruda continues success with new Phase 3 data in adjuvant melanoma

MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage III melanoma. It is the third such reveal in weeks, following the drug’s success as a monotherapy in NSCLC with any PD-L1 expression but failure as a combo therapy in unresectable or metastatic melanoma.

Bron: Pharmafile Meer lezen »

GSK inks agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics

GSK, a science─led global healthcare company, and Orchard Therapeutics, a privately held clinical─stage biotechnology company, both jointly announced a strategic agreement.

Bron: Pharma Biz Meer lezen »

Bayer contraceptive implant public backlash brings results

Bayer’s permanent contraceptive device, Essure, has been at the centre of a public backlash for a number of years, with women how had the device implanted suggesting that they were had not been made aware of the risks.

Bron: Pharmafile Meer lezen »

Lilly and Sigilon team up in $473m+ deal to ‘cure’ diabetes

Eli Lilly and Sigilon Therapeutics have announced a partnership that looks to break new ground in the management of type 1 diabetes, by using stem cells to provide a long-term treatment solution.  

Bron: Pharmafile Meer lezen »

Takeda move for Shire looks increasingly likely

Takeda’s surprise announcement that it was weighing up a move for Shire had some analysts sceptical about whether the Japanese company could pull off such a larger acquisition.  

Bron: Pharmafile Meer lezen »

Eli Lilly’s Cyramza rallies back in liver cancer with biomarker win

After Eli Lilly’s Cyramza flopped a phase 3 liver cancer trial in 2014, the company went back to the drawing board to design a trial for a specific subpopulation. Nearly four years later, it’s back with a win.

Bron: FiercePharma Meer lezen »

Het effect van de GDPR op display advertising

Dit artikel is onderdeel van de serie over GDPR en het effect op digital marketing. In deze editie zoom ik in op de effecten op (programmatic) display advertising. Omdat hier al heel veel over is gepubliceerd, zoeken we naar aandachtspunten waar minder over geschreven wordt, maar die ook wel degelijk van belang zijn.

Bron: Meer lezen »

« Oudere artikelen |